Alnylam Pharmaceuticals, Inc. (ALNY)
399.83
+1.13
(+0.28%)
USD |
NASDAQ |
Dec 24, 10:44
Alnylam Pharmaceuticals SG&A Expense (TTM): 1.181B for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Biogen, Inc. | 2.431B |
| Insmed, Inc. | 631.20M |
| Pfizer Inc. | 13.91B |
| Glaukos Corp. | 306.05M |
| BridgeBio Pharma, Inc. | 467.92M |